| Biologic Therapy |
1 |
1 |
| CAR-T |
0 |
0.99 |
| Toxicology |
0 |
0.73 |
| Neurotoxicity |
0 |
0.98 |
| Non-Hodgkin Lymphoma (NHL) |
0 |
0.3 |
| Cancer |
0 |
0.25 |
| Lymphoma |
0 |
0.25 |
| Washington |
0 |
0.25 |
| Cerebrovascular Accident |
0 |
0.23 |
| B-Cell Lymphoma |
0 |
0.22 |
| Injury |
0 |
0.19 |
| Patient Safety |
0 |
0.19 |
| Wound Management |
0 |
0.19 |
| Adverse Effects |
0 |
0.13 |
| Hospital |
0 |
0.13 |
| Leukemia |
0 |
0.13 |
| Multiple Myeloma |
0 |
0.13 |
| Multiple Sclerosis |
0 |
0.13 |
| Plasma |
0 |
0.13 |
| Alzheimer Disease |
0 |
0.06 |
| Amyotrophic Lateral Sclerosis |
0 |
0.06 |
| Antigens |
0 |
0.06 |
| Biomarker |
0 |
0.06 |
| Delirium |
0 |
0.06 |
| Headache |
0 |
0.06 |
| Muscular Atrophy |
0 |
0.06 |
| Neurodegenerative Diseases |
0 |
0.06 |
| Plantar |
0 |
0.06 |
| Receptors |
0 |
0.06 |
| Seizure |
0 |
0.06 |
| Steroids |
0 |
0.06 |
| Texas |
0 |
0.06 |